Scott Gottlieb, MD
When Scott Gottlieb, MD, stepped down from his post as FDA commissioner in April 2019, he had earned praise and respect for his willingness to take on important issues, such as opioid regulation1
and the marketing of tobacco products to youths2
He said the entire field of cancer care is being transformed through new technology. Not just new therapeutics, but new diagnostic tools are also profoundly changing the way doctors practice oncology.
Timeline. Highlights of Scott Gottlieb's Tenure at FDA
... to read the full story